11/17
01:42 pm
imnn
IMNN: R&D Day Highlights Potential for IMNN-001… [Yahoo! Finance]
Low
Report
IMNN: R&D Day Highlights Potential for IMNN-001… [Yahoo! Finance]
11/13
07:51 am
imnn
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/13
07:45 am
imnn
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
11/12
11:07 am
imnn
Imunon Q3 2025 Earnings Preview [Seeking Alpha]
Low
Report
Imunon Q3 2025 Earnings Preview [Seeking Alpha]
11/10
05:13 pm
imnn
Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript [Seeking Alpha]
Low
Report
Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript [Seeking Alpha]
11/10
01:30 pm
imnn
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
Low
Report
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
11/10
07:59 am
imnn
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer [Yahoo! Finance]
High
Report
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer [Yahoo! Finance]
11/10
07:30 am
imnn
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
Medium
Report
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
11/7
08:05 am
imnn
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
Low
Report
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
11/6
08:38 am
imnn
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 [Yahoo! Finance]
Low
Report
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 [Yahoo! Finance]
11/6
08:05 am
imnn
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
Low
Report
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
11/4
08:05 am
imnn
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Low
Report
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
10/30
08:00 am
imnn
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
Medium
Report
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
10/23
10:01 am
imnn
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
Low
Report
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
10/20
08:05 am
imnn
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Low
Report
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
10/17
08:10 am
imnn
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
Medium
Report
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
10/14
08:58 am
imnn
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress [Yahoo! Finance]
Low
Report
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress [Yahoo! Finance]
10/14
08:20 am
imnn
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Low
Report
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
10/8
12:25 pm
imnn
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Imunon (NASDAQ:IMNN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
9/24
05:44 am
imnn
Imunon's IL-12 gene therapy changes “cold” tumour microenvironment to “hot” [Yahoo! Finance]
Low
Report
Imunon's IL-12 gene therapy changes “cold” tumour microenvironment to “hot” [Yahoo! Finance]
9/23
01:54 pm
imnn
IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment… [Yahoo! Finance]
Low
Report
IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment… [Yahoo! Finance]
9/22
08:43 am
imnn
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift [Yahoo! Finance]
Medium
Report
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift [Yahoo! Finance]
9/22
08:05 am
imnn
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Medium
Report
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
9/19
08:37 am
imnn
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research [Yahoo! Finance]
Low
Report
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research [Yahoo! Finance]
9/19
08:05 am
imnn
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
High
Report
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research